





TECHNICAL REPORT ON THE EVALUATION OF PROPOSALS PRESUMED TO BE ANALORMAL OR DISPROPRIATE IN CONTRACTING FOR THE SERVICE OF DNA AND RNA SEQUENCING AND SPECIALIZED BIOINFORMATIC ANALYSIS FROM TUMOR SAMPLES AND WHOLE BLOOD IN THE FUNDACIÓ HOSPITAL UNIVERSITARI VALL HEBRON - INSTITUT DE RECERCA (VHIR).

Proyecto "PI23/01045", financiado por el Instituto de Salud Carlos III (ISCIII) y cofinanciado por la Unión Europea.



2025-031 DNA AND RNA SEQUENCING (PI23/01045)


On 26 September of 2025, the justification of the allegedly abnormal or disproportionate proposals of the company **EDINBURGH GENETICS LIMITED**, bidder of the present tender process relating to the Next generation sequencing service and data analysis and report including DNA and RNA sequencing from human tumour samples, paired with sequencing of peripheral blood samples as a control sample by the Project Pl23/01045 titled "*Plataforma integrativa multiómica para la identificación de biomarcadores predictivos de respuesta a quimioterapia e inmunoterapia en cáncer de mama triple negativo temprano (PORTRAIT-TNBC)*" of the Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR), funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union.

The evaluation and motivation of the bids of the aforementioned company is detailed below, which has been carried out taking into account the specifications contemplated in the document of the requirement and under the protection of article 149.4 of Law 9/2017, of 8 November on Public Sector Contracts, which states that the conditions of the bid that are likely to determine the low level of the price or costs of this and, particularly, in the one referred to in the following values:

- a) the economy made possible by the manufacturing process, the services provided or the method of construction
- b) the technical solutions adopted and the exceptionally favourable conditions available to it for the supply of the products, the provision of the services or the execution of the work
- c) the innovativeness and originality of the solutions proposed for the supply of the products, the provision of the services or the execution of the works
- d) Compliance with applicable environmental, social or labour and subcontracting obligations, with prices below market prices or prices that do not comply with the provisions of Article 201 not being justifiable.
- e) Or the possible obtaining of State aid.

The justification for the allegedly abnormal or disproportionate offer is explained below:

EDINBURGH GENETICS LIMITED







While the proposal from Edinburgh Genetics Limited outlines costs and includes some broad claims about efficiency and expertise, it fails to deliver a thorough or specific rationale for a price that is considerably below market averages. It is a very general and non-specific justification addressed to the tender in question. For example, it includes price for sample shipping that is actually out of this offer. The justification lacks specific details about the technologies they would be using, there being a broad range of possibilities (and prices) for low or high amounts of starting material, etc. The company states that it has established protocols, automated processes, and cost-saving measures, yet it does not provide concrete evidence (like cost comparisons, productivity metrics, or unique technological benefits) that would account for significant price reduction. The proposal indicates that the stated price is "within the range we charge other customers" and "consistent with market norms." This implies that the price is not unusually low, thereby not addressing concerns about a potentially disproportionate low offer. There is no thorough explanation of how each component cost is reduced in comparison to industry standards, nor is there any documentation that would corroborate the claim of efficiency or justify a price beneath typical market rates. Their justification primarily reiterates compliance and experience but does not show the level of detail or evidence necessary to justify a price that is significantly lower than what is customary in the market.

In view of the above, it is decided to reject the justification submitted by the company **EDINBURGH GENETICS LIMITED**.

Barcelona, 26 September of 2025

RESPONSIBLE

Infl de (line

Dr. Ana Mafalda Antunes de Melo Oliveira

IP of the Project PI23/01045

Clinical Research Scientist and Medical Oncologist in the Breast Cancer Group at VHIO Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca